High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations
暂无分享,去创建一个
F. Ceccherini‐Silberstein | F. Gago | A. Antinori | M. Ciccozzi | A. Monforte | J. Balzarini | F. Rodríguez-Barrios | C. Perno | A. Bertoli | V. Svicher | M. Santoro | C. Gori | R. D'arrigo | Fátima Rodríguez-Barrios
[1] T. Liljefors,et al. Identification of a putative binding site for 5-alkyl-benzothiadiazides in the AMPA receptor dimer interface. , 2007, Journal of molecular graphics & modelling.
[2] E. De Clercq,et al. The Amino Acid Asn136 in HIV-1 Reverse Transcriptase (RT) Maintains Efficient Association of Both RT Subunits and Enables the Rational Design of Novel RT Inhibitors , 2005, Molecular Pharmacology.
[3] Valentina Svicher,et al. Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors , 2005, Antimicrobial Agents and Chemotherapy.
[4] S. Sarafianos,et al. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. , 2004, Current opinion in structural biology.
[5] F. Ceccherini‐Silberstein,et al. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure , 2004, AIDS.
[6] Matthew J. Gonzales,et al. Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing , 2004, Antimicrobial Agents and Chemotherapy.
[7] T. Steitz,et al. Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[8] Christopher J. Lee,et al. Positive Selection Detection in 40,000 HumanImmunodeficiency Virus (HIV) Type 1 Sequences Automatically IdentifiesDrug Resistance and Positive Fitness Mutations in HIV Proteaseand ReverseTranscriptase , 2004, Journal of Virology.
[9] Joseph P. Bielawski,et al. Widespread Adaptive Evolution in the Human Immunodeficiency Virus Type 1 Genome , 2003, Journal of Molecular Evolution.
[10] Victoria A Johnson,et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] T. Darden,et al. Mutations Proximal to the Minor Groove-Binding Track of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Differentially Affect Utilization of RNA versus DNA as Template , 2003, Journal of Virology.
[12] Thomas D. Wu,et al. Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.
[13] Thomas D. Wu,et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors , 2003, AIDS.
[14] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[15] Kamalendra Singh,et al. Insertion of a small peptide of six amino acids into the β7–β8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities , 2002, BMC Biochemistry.
[16] Robert W. Shafer,et al. Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.
[17] G. Ippolito,et al. Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation , 2002, AIDS.
[18] P Pezzotti,et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. , 2001, The Journal of infectious diseases.
[19] R. Shafer,et al. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. , 2001, The Journal of infectious diseases.
[20] Zehava Grossman,et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B , 2001, AIDS.
[21] K. Ariyoshi,et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients , 2001, AIDS.
[22] R. Esnouf,et al. Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT. , 2001, Virology.
[23] T. Talele,et al. The beta7-beta8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. , 2001 .
[24] F. Gago,et al. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. , 2001, Journal of medicinal chemistry.
[25] K. Hertogs,et al. Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. , 2001, AIDS.
[26] Julio S. G. Montaner,et al. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort , 2001, AIDS.
[27] K. Hertogs,et al. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting , 2001 .
[28] D I Stuart,et al. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.
[29] S. Goff,et al. Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[31] Y. Cao,et al. HIV-1 drug resistance in newly infected individuals. , 1999, JAMA.
[32] S. Yerly,et al. Transmission of antiretroviral-drug-resistant HIV-1 variants , 1999, The Lancet.
[33] M A Wainberg,et al. HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. , 1999, Archives of biochemistry and biophysics.
[34] R. Esnouf,et al. Mutational Analysis of Tyr-318 within the Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket of Human Immunodeficiency Virus Type I Reverse Transcriptase* , 1998, The Journal of Biological Chemistry.
[35] G L Verdine,et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.
[36] R. Lee,et al. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. , 1998, Biochemistry.
[37] P. Boyer,et al. Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase. , 1998, Journal of molecular biology.
[38] Martin A. Nowak,et al. The frequency of resistant mutant virus before antiviral therapy , 1998, AIDS.
[39] G J Pielak,et al. A genetic approach for identifying critical residues in the fingers and palm subdomains of HIV-1 reverse transcriptase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] R. Bambara,et al. Mutations within the Primer Grip Region of HIV-1 Reverse Transcriptase Result in Loss of RNase H Function* , 1997, The Journal of Biological Chemistry.
[41] S. L. Le Grice,et al. Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. , 1996, Biochemistry.
[42] A. D. Clark,et al. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.
[43] Samuel H. Wilson,et al. Role of the "Helix Clamp" in HIV-1 Reverse Transcriptase Catalytic Cycling as Revealed by Alanine-scanning Mutagenesis (*) , 1996, The Journal of Biological Chemistry.
[44] A. Hughes,et al. Natural selection on the gag, pol, and env genes of human immunodeficiency virus 1 (HIV-1). , 1995, Molecular biology and evolution.
[45] C. Hutchison,et al. Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1. , 1995, Nucleic acids research.
[46] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[47] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[48] Samuel H. Wilson,et al. Structure/function studies of human immunodeficiency virus type 1 reverse transcriptase. Alanine scanning mutagenesis of an alpha-helix in the thumb subdomain. , 1994, The Journal of biological chemistry.
[49] H. Heumann,et al. The 'helix clamp' in HIV-1 reverse transcriptase: a new nucleic acid binding motif common in nucleic acid polymerases. , 1994, Nucleic acids research.
[50] P. Boyer,et al. Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. , 1994, Journal of molecular biology.
[51] Jianping Ding,et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.
[52] T. Steitz,et al. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[53] P. Boyer,et al. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[54] T. Kunkel,et al. Structure/function studies of HIV-1(1) reverse transcriptase: dimerization-defective mutant L289K. , 1993, Biochemistry.
[55] A. D. Clark,et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[56] P. Boyer,et al. Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase , 1992, Journal of virology.
[57] T. Steitz,et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.
[58] R. Goody,et al. RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms , 1992, FEBS letters.
[59] J. Maizel,et al. HIV-1 reverse transcriptase: structure predictions for the polymerase domain. , 1990, AIDS research and human retroviruses.
[60] M. A. McClure,et al. Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[61] D. Birx,et al. Lost in translation: implications of HIV-1 codon usage for immune escape and drug resistance. , 2004, AIDS reviews.
[62] E. De Clercq,et al. Antivirals and antiviral strategies. , 2004, Nature reviews. Microbiology.
[63] Amalio Telenti,et al. Update of the drug resistance mutations in HIV-1: 2004. , 2004, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[64] S. Yerly,et al. Travel and the spread of HIV-1 genetic variants. , 2003, The Lancet. Infectious diseases.
[65] R. Shafer,et al. Drug resistance mutations in HIV-1. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[66] Soriano,et al. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. , 2001, AIDS.
[67] B. Larder,et al. Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .
[68] L. Loeb,et al. FUNCTIONAL MUTANTS OBTAINED BY RANDOM MUTAGENESIS COUPLED WITH GENETIC SELECTION IN ESCHERICHIA COLI , 1996 .